Inspire Medical Systems (NYSE:INSP) Price Target Raised to $130.00 at Mizuho

Inspire Medical Systems (NYSE:INSP) had its price target upped by Mizuho from $110.00 to $130.00 in a research report report published on Wednesday morning, Marketbeat.com reports. They currently have an outperform rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Royal Bank Of Canada lowered their price target on shares of Inspire Medical Systems from $150.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, November 4th. Wolfe Research raised Inspire Medical Systems from a “peer perform” rating to an “outperform” rating and set a $180.00 target price for the company in a research report on Tuesday, November 25th. Stifel Nicolaus set a $110.00 price target on shares of Inspire Medical Systems and gave the company a “buy” rating in a research report on Monday, November 24th. Weiss Ratings reissued a “sell (d+)” rating on shares of Inspire Medical Systems in a report on Wednesday, December 10th. Finally, UBS Group set a $89.00 target price on Inspire Medical Systems and gave the stock a “neutral” rating in a research note on Monday, September 22nd. Eleven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $138.88.

Inspire Medical Systems Stock Performance

INSP opened at $118.34 on Wednesday. Inspire Medical Systems has a fifty-two week low of $70.77 and a fifty-two week high of $216.01. The firm has a 50-day moving average of $98.86 and a 200 day moving average of $104.04. The firm has a market cap of $3.44 billion, a P/E ratio of 80.50, a PEG ratio of 13.31 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($0.15) by $0.53. The business had revenue of $224.50 million for the quarter, compared to analyst estimates of $220.39 million. Inspire Medical Systems had a net margin of 5.05% and a return on equity of 9.41%. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.60 earnings per share. Equities research analysts predict that Inspire Medical Systems will post 2.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Shawn Mccormick sold 2,000 shares of the business’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.48, for a total transaction of $254,960.00. Following the completion of the transaction, the director directly owned 26,046 shares in the company, valued at $3,320,344.08. The trade was a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.10% of the stock is currently owned by insiders.

Institutional Trading of Inspire Medical Systems

A number of large investors have recently modified their holdings of INSP. Dragoneer Investment Group LLC grew its holdings in shares of Inspire Medical Systems by 81.4% during the second quarter. Dragoneer Investment Group LLC now owns 2,354,411 shares of the company’s stock worth $305,532,000 after purchasing an additional 1,056,808 shares in the last quarter. Wasatch Advisors LP lifted its position in Inspire Medical Systems by 7.2% during the second quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after purchasing an additional 110,288 shares during the last quarter. William Blair Investment Management LLC grew its stake in Inspire Medical Systems by 68.7% in the 3rd quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company’s stock worth $96,280,000 after buying an additional 528,404 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Inspire Medical Systems by 214.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,112,925 shares of the company’s stock worth $177,267,000 after buying an additional 759,090 shares during the last quarter. Finally, Deerfield Management Company L.P. increased its holdings in shares of Inspire Medical Systems by 648.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after buying an additional 907,694 shares during the last quarter. Institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.